0001567619-18-001205.txt : 20180815
0001567619-18-001205.hdr.sgml : 20180815
20180815172324
ACCESSION NUMBER: 0001567619-18-001205
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180813
FILED AS OF DATE: 20180815
DATE AS OF CHANGE: 20180815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bilenker Joshua H.
CENTRAL INDEX KEY: 0001612312
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 181021792
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2018-08-13
0
0001581720
Loxo Oncology, Inc.
LOXO
0001612312
Bilenker Joshua H.
C/O LOXO ONCOLOGY, INC.
ONE LANDMARK SQUARE, SUITE 1122
STAMFORD
CT
06901
1
1
0
0
President & CEO
Common Stock
2018-08-13
4
M
0
10000
1.184
A
145407
D
Common Stock
2018-08-13
4
S
0
1600
157.6677
D
143807
D
Common Stock
2018-08-13
4
S
0
4233
158.5098
D
139574
D
Common Stock
2018-08-13
4
S
0
3367
159.6267
D
136207
D
Common Stock
2018-08-13
4
S
0
800
160.4862
D
135407
D
Common Stock
2018-08-14
4
M
0
10000
1.184
A
145407
D
Common Stock
2018-08-14
4
S
0
1600
159.1263
D
143807
D
Common Stock
2018-08-14
4
S
0
7100
159.9311
D
136707
D
Common Stock
2018-08-14
4
S
0
1300
160.7508
D
135407
D
Common Stock
30000
I
By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018
Employee Stock Option (Right to Buy)
1.184
2018-08-13
4
M
0
10000
0
D
2023-11-14
Common Stock
10000
83932
D
Employee Stock Option (Right to Buy)
1.184
2018-08-14
4
M
0
10000
0
D
2023-11-14
Common Stock
10000
73932
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.99 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.13 to $160.07 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.17 to $160.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.41 to $159.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.47 to $160.46 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.47 to $161.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The options have fully vested and are immediately exercisable.
/s/Jennifer Burstein, by power of attorney
2018-08-14